Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.
Deciding Management for Early HER2-Positive Breast Cancer
Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa study of subcutaneous trastuzumab and pertuzumab in patients with HER2-positive breast cancer.
Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.
Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.
William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.